media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

1.6 billion! A well-known Vietnamese pharmaceutical company was acquired

Recently, Livzon Pharmaceutical announced that its wholly-owned overseas subsidiary LIAN SGP signed an agreement with the sellers (SK, Sunrise and KBA) to acquire 64.81% of the shares of Imexpharm Corporation (IMP), a Vietnamese listed company held by the sellers, at a purchase price of 573.08 billion Vietnamese dong (approximately RMB 1.587 billion). Public information shows that IMP is a leading pharmaceutical company in Vietnam, founded in 1977 and listed on the Ho Chi Minh City Stock Exchange in 2006. According to the list of the top ten well-known pharmaceutical companies in 2024 published by Vietnam Report Joint Stock Company (Vietnam Report), IMP ranked third. Imexpharm is mainly engaged in the research and development, production and sales of drugs, and its products mainly include antibiotics, cardiovascular and cerebrovascular drugs, etc. At present, Imexpharm has 4 factories and 25 retail branches in various provinces and cities in Vietnam. In terms of market ...
- Source: drugdu
- 47
- May 29, 2025
PD-1+LAG3 work together to “break through”

The 2025 ASCO Annual Meeting is about to be held. At present, the regular abstracts have been released to the public, and many domestic new drugs have performed well. Among them, LBL-007 of Weilizhibo has made its debut again with breakthrough data. This is the fifth consecutive year that the drug has been selected for the ASCO meeting. LBL-007 is a fully human IgG4 monoclonal antibody targeting LAG3. Its clinical progress ranks among the top three in the world (except for the only LAG3-targeted drug on the market). It is also the first antibody of its kind to be proven to be effective against nasopharyngeal carcinoma. Clinical data show that LBL-007 combined with first-line therapy for NPC patients has an ORR of 83.3% and a median PFS of 15.8 months, which is significantly higher than the existing standard regimen. With its excellent safety and efficacy, LBL-007 is expected to become ...
- Source: drugdu
- 54
- May 29, 2025
BPE Shenzhen 2025

Organiser: Guangdong High-tech Enterprises Association Time：November 14th – 16th, 2025 address：Shenzhen World Exhibition & Convention Center (Bao’an New Hall), No. 1 Zhancheng Road, Fuhai Street, Bao’an District, Shenzhen City, Guangdong Province Exhibition hall：Shenzhen World Exhibition & Convention Center (Bao’an New Hall) Product range: Laboratory Technology and Equipment Zone: Microbial strains, incubation and cultivation equipment, culture media, high-throughput screening equipment, gene detection instruments, gene sequencing instruments, genetic engineering technology and equipment, separation and purification systems, bioprocess systems, fermenters, cell culture systems, cell reactors, bioreactors, GLP/GMP equipment, pre-treatment equipment, biochemical analysis instruments, measurement and control devices, bioinformatics technology, bio-imaging systems, biochips, reagents, preservation equipment, laboratory environmental equipment, laboratory information management systems, etc. Engineering Technology and Equipment Zone: Fermenters, bioreactors, cell reactors, enzyme reactors, cell culture equipment, culture media, saccharification equipment, filtration and separation equipment, extraction and purification equipment, mass transfer, evaporation and crystallization, drying, stirring, mixing, grinding, instrumentation and industrial automation ...
- Source: drugdu
- 66
- May 29, 2025
Integrating pharmacogenomics into everyday clinical practice can transform patient care

Pharmacogenomics studies how individuals respond to drugs based on their genetic code. Using that knowledge to guide prescribing in routine care could lead to better outcomes for patients and save money for health systems. Generating pharmacogenomic data in the laboratory is relatively straightforward, but a major challenge is making that information available to frontline healthcare professionals in a clinically relevant format and timeframe. This has meant that, to date, only a limited numbers of patients have been able to benefit from such individually optimised treatments. Dr. John McDermott, NIHR Academic Clinical Lecturer at the University of Manchester, Manchester, UK, will describe to the annual congress of the European Society of Human Genetics today (Tuesday) how he and colleagues, as part of the NHS-England Network of Excellence for Pharmacogenomics & Medicines Optimisation, have pioneered an approach to integrate genomic data into electronic health records in both GP practices and hospitals. This ...
- Source: drugdu
- 54
- May 28, 2025
MRI scans reveal why young women face higher risk for eating disorders

Breakthrough MRI scans reveal hidden hypothalamic changes in young women, shedding light on the biological roots of anorexia and obesity, and paving the way for targeted treatments. A recent editorial feature published in the American Journal of Clinical Nutrition discusses the use of a novel imaging technique to investigate how certain structural features of the hypothalamus affect eating behaviors. A new approach to studying the hypothalamus Women are more likely to develop eating disorders like anorexia nervosa than men, particularly during puberty. Despite this disproportional occurrence, few studies have investigated the role of the female brain in neuroscience and psychiatry. The hypothalamus is a small, heterogeneous brain structure in the diencephalon that regulates homeostatic and hedonic functions involved in feeding behaviors. Current imaging techniques are limited in their ability to capture nuclei subsegmentation within the hypothalamus. As a result, most studies investigating the role of the hypothalamus have been conducted ...
- Source: drugdu
- 58
- May 28, 2025
Guangdong Province launches quantity based procurement, including 170 drugs and 248 product specifications | early reference materials for pharmaceuticals

No.1 Guangdong Province launches quantity based procurement, including 170 drugs and 248 product specifications Recently, the Guangdong Provincial Drug Trading Center issued a notice stating that 22 provinces (including the Corps) within the alliance will continue to purchase 170 varieties and 248 specifications of drugs, except for those that overlap with national procurement (including national joint procurement), national medical insurance negotiated drugs (including bidding drugs), and national basic medical insurance drug catalogs. This procurement has cancelled A/B purchase orders and opted for group bidding. Comment: Guangdong Province has launched a 22 province alliance drug procurement, involving 170 varieties. The A/B purchase orders have been cancelled and grouped for bidding, which may promote drug price reduction and industry integration. NO.2 Shandong Heda: The US Department of Commerce has preliminarily ruled that the anti-dumping tax rate obtained by the company’s wholly-owned subsidiary is 172.24% On the evening of May 26th, Shandong ...
- Source: drugdu
- 51
- May 28, 2025
21 Health News Daily | Yuheng Pharmaceutical and Xinghe Pharmaceutical signed a promotion agreement; Shareholders of Chengdu Pioneer and Aojing Medical reduce their holdings

Policy Tendence The National Medical Products Administration issued a document requiring the implementation of the “Quality Management Standards for Medical Device Network Sales” On May 26th, the National Medical Products Administration announced that the “Quality Management Standards for Online Sales of Medical Devices” (hereinafter referred to as the “Standards”) will officially come into effect on October 1, 2025. Drug regulatory departments at all levels should guide online sales operators and e-commerce platform operators to actively carry out internal training and assessment, focusing on the comprehensiveness of the quality management system coverage of online sales operators, the standardization of product information display, the completeness of online sales related records, as well as the establishment of full process quality management records, verification and updating of network operator files, and the monitoring and risk consultation of medical device quality and safety risks within the platform. Enterprises should conduct key self inspections. Medical device ...
- Source: drugdu
- 58
- May 28, 2025
Kexing Biotech’s wholly-owned subsidiary is approved to conduct clinical trials of GB18 injection

On May 26, Kexing Pharmaceuticals issued an announcement that recently, the company’s wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving it to conduct clinical trials of “GB18 Injection”. The injection is an innovative drug targeting GDF15, designed to treat tumor cachexia. Preclinical data show that GB18 injection has obvious differentiated advantages, can effectively reverse weight loss caused by tumor cachexia, and improve muscle and fat quality. In the first quarter of 2025, Kexing Biotech achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 25.58 million yuan. https://finance.eastmoney.com/a/202505263414629127.html
- Source: drugdu
- 52
- May 28, 2025
Angel Yeast plans to invest 230 million yuan to develop serum-free cell culture medium technology

May 26, Angel Yeast issued an announcement that it plans to implement a key technology research project for serum-free cell culture medium. The total investment of the project is estimated at RMB 230 million, aiming to promote the development of the company’s biotechnology and meet the needs of antibodies, vaccines and recombinant proteins. Other biological products The project will explore the existing synthetic biology The pilot platform has been upgraded and renovated to add a serum-free cell culture medium preparation platform and a core raw material refining and purification platform. It is expected to produce 200 tons of dry powder serum-free cell culture medium and 100,000 liters of liquid serum-free cell culture medium annually. The project construction period is expected to be 30 months, and it is scheduled to be put into production in 2027. The funds will come from the company’s own funds. In the first quarter of 2025, ...
- Source: drugdu
- 50
- May 28, 2025
A new starting point for Hengrui

Hengrui Medicine was founded in 1970. Its predecessor was a small pharmaceutical factory in Lianyungang, Jiangsu (Lianyungang Pharmaceutical Factory). In 1982, Sun Piaoyang joined Lianyungang Pharmaceutical Factory and took office as the new factory director in 1990. Under his leadership, Hengrui Medicine gradually grew from generic drugs to innovative drugs, and became a leader in China’s pharmaceutical field. In 2020, Hengrui Medicine’s market value exceeded 600 billion yuan, driven by innovative products such as carrelizumab. However, with the advancement of national centralized procurement and medical insurance negotiations, Hengrui Medicine’s performance faces severe challenges, and its revenue and net profit have not yet returned to the highs of Q4 2020. The revenue of the generic drug business has shrunk sharply in the past few years, bringing Hengrui Medicine’s performance into its darkest moment, with revenue falling from 27.73 billion yuan in 2020 to 22.82 billion yuan in 2023. In 2024, although ...
- Source: drugdu
- 51
- May 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.